![Christopher Gerry](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 25 960 $ in data 31/07/2026
Christopher W.
Gerry is currently Secretary & General Counsel at Faeth Therapeutics, Inc., a position starting in 2026.
Formerly, Mr. Gerry was Vice President & Deputy General Counsel at AVROBIO, Inc. from 2021 to 2022 and an Associate at Cooley LLP from 2013 to 2019.
Education includes undergraduate studies at Dickinson College and graduate studies at Boston University School of Law.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 10/06/2026 | 953 ( 0% ) | 25 960 $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| FAETH THERAPEUTICS, INC. | Consigliere Generale | 01/07/2022 |
| Società | Posizione | Fine |
|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Corporate Officer/Principal | 01/07/2022 |
Cooley LLP
 Cooley LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01/10/2019 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Dickinson College
 Dickinson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Boston University School of Law
 Boston University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVROBIO, Inc.
 AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose | Health Technology |
Sensei Biotherapeutics, Inc.
 Sensei Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops immunotherapies for cancers and infectious disease | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
